Key result
Early reductions in sensory nerve action potential amplitudes (>11.5% in the median nerve) independently predicted the development of severe grade-3 oxaliplatin-induced peripheral neuropathy (OR 5.603).
Why the study?
What are the long-term outcomes and predictors of severe oxaliplatin-induced peripheral neuropathy in patients with colon cancer?
Cohort (n=69)
No
What are the long-term outcomes and predictors of severe oxaliplatin-induced peripheral neuropathy in patients with colon cancer?
Odds Ratio: 5.603 (95% CI 1.174–26.745)
p-value: p=0.031
Early changes in nerve conduction studies can predict the development of severe oxaliplatin-induced peripheral neuropathy, which persists in more than half of patients at 1 year.
Early NCS changes may flag high-risk patients for severe oxaliplatin neuropathy; hypothesis-generating for prospective monitoring trials before practice change.
BACKGROUND AND PURPOSE: The objective of this study was to determine the incidence and long-term outcomes of oxaliplatin-induced peripheral neuropathy (OIPN), as well as predictors of its severe form. METHODS: Sixty-nine patients who were taking oxaliplatin for colon cancer were prospectively followed prior to starting chemotherapy and after 4, 8, and 12 cycles of chemotherapy. Thirty-six patients completed the follow-up at 1 year after the end of chemotherapy. The patients were assessed using clinical assessment scales and nerve conduction studies (NCS) at each follow-up visit. RESULTS: By applying the National Cancer Institute Common Toxicity criteria, OIPN was classified as grade 1 in 30 (44%) patients, grade 2 in 25 (36%), and grade 3 in 10 (14%) at the completion of therapy. At 1 year after the treatment, OIPN of grades 1, 2, and 3 was found in 50, 3, and 11% of the patients, respectively. Multivariate analysis showed that reductions of the amplitude of the sensory action potential of >11.5% in the median nerve between baseline and four cycles of chemotherapy (odds ratio=5.603, p=0.031) and of >22.5% in the sural nerve between four and eight cycles of chemotherapy (odds ratio=5.603, p=0.031) were independently associated with the risk of developing grade-3 OIPN. CONCLUSIONS: While the severity of OIPN can improve after oxaliplatin discontinuation, more than half of the patients in this study still had OIPN at 1 year after discontinuation. Early changes in the NCS results for sensory nerves can predict the development of severe OIPN during treatment.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2018) conducted a cohort in Colon cancer (n=69). Early reduction in sensory nerve action potential amplitude (>11.5% in median nerve) vs. No early reduction was evaluated on Development of grade-3 oxaliplatin-induced peripheral neuropathy (OR 5.603, 95% CI 1.174-26.745, p=0.031). Early reductions in sensory nerve action potential amplitudes (>11.5% in the median nerve) independently predicted the development of severe grade-3 oxaliplatin-induced peripheral neuropathy (OR 5.603).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: